MXPA03008154A - Novedoso adyuvante de vacuna de proteosoma-liposacarido. - Google Patents

Novedoso adyuvante de vacuna de proteosoma-liposacarido.

Info

Publication number
MXPA03008154A
MXPA03008154A MXPA03008154A MXPA03008154A MXPA03008154A MX PA03008154 A MXPA03008154 A MX PA03008154A MX PA03008154 A MXPA03008154 A MX PA03008154A MX PA03008154 A MXPA03008154 A MX PA03008154A MX PA03008154 A MXPA03008154 A MX PA03008154A
Authority
MX
Mexico
Prior art keywords
liposaccharide
proteosome
novel
vaccine adjuvant
variety
Prior art date
Application number
MXPA03008154A
Other languages
English (en)
Inventor
Rioux Clement
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Publication of MXPA03008154A publication Critical patent/MXPA03008154A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un complejo adyuvante compuesto de proteosomas de proteina de membrana externa bacteriana, acomplejados con ligosacarido bactariano, se prepara para contener las partes componentes bajo una variedad de condiciones. El complejo puede formularse con material antigenico para formar composiciones inmunagenicas e inmunoterapeuticas. Una respuesta inmune inducida incluye anticuerpos protectores y/o citocinas de tipo I se muestran para una variedad de protocolos.
MXPA03008154A 2001-03-09 2002-03-11 Novedoso adyuvante de vacuna de proteosoma-liposacarido. MXPA03008154A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27423201P 2001-03-09 2001-03-09
US32729701P 2001-10-09 2001-10-09
PCT/US2002/007108 WO2002072012A2 (en) 2001-03-09 2002-03-11 A novel proteosome-liposaccharide vaccine adjuvant

Publications (1)

Publication Number Publication Date
MXPA03008154A true MXPA03008154A (es) 2004-11-12

Family

ID=26956684

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008154A MXPA03008154A (es) 2001-03-09 2002-03-11 Novedoso adyuvante de vacuna de proteosoma-liposacarido.

Country Status (9)

Country Link
US (2) US7524509B2 (es)
EP (1) EP1372706B1 (es)
JP (2) JP4137640B2 (es)
AT (1) ATE489968T1 (es)
AU (1) AU2002245636B2 (es)
CA (1) CA2438425C (es)
DE (1) DE60238471D1 (es)
MX (1) MXPA03008154A (es)
WO (1) WO2002072012A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
EP1622641A2 (en) * 2003-05-05 2006-02-08 ID Biomedical Corporation of Quebec Vaccinating against infectious diseases using proteosomes
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1667713A1 (en) * 2003-09-15 2006-06-14 ID Biomedical Corporation of Quebec Measles subunit vaccine
US8173140B2 (en) * 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CU23420A1 (es) * 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
JP5274011B2 (ja) * 2004-06-25 2013-08-28 アイディー バイオメディカル コーポレイション オブ ケベック 神経障害を治療するための組成物および方法
US20060286124A1 (en) * 2004-06-30 2006-12-21 Id Biomedical Corporation Of Quebec Vaccine compositions and methods of treating coronavirus infection
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
WO2009062132A2 (en) 2007-11-09 2009-05-14 California Institute Of Technology Immunomodulating compounds and related compositions and methods
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
SI2222710T1 (sl) 2007-12-24 2016-11-30 Id Biomedical Corporation Of Quebec Rekombinatni RSV antigeni
WO2010003219A1 (en) * 2008-06-17 2010-01-14 Universite Laval Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines
US20110171259A1 (en) 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
JP2012524910A (ja) * 2009-04-23 2012-10-18 カリフォルニア インスティチュート オブ テクノロジー 免疫調節物質の同定方法及びシステム
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
CA2766211A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CA2815275C (en) 2010-10-27 2023-09-19 Glaxosmithkline Biologicals S.A. Immunogenic compositions derived from shigella
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
CA2977493C (en) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08508247A (ja) * 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
CA2172507C (en) 1993-10-22 2008-12-02 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
EP0929678A2 (en) 1996-07-10 1999-07-21 ID Biomedical Corporation of Maryland Protein and peptide vaccines for inducing mucosal immunity
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
ATE331530T1 (de) * 2000-02-15 2006-07-15 Id Biomedical Corp Quebec Proteasom-influenzavirus-impfstoffzusammensetzu g
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1667713A1 (en) * 2003-09-15 2006-06-14 ID Biomedical Corporation of Quebec Measles subunit vaccine
US8173140B2 (en) * 2003-10-22 2012-05-08 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
US20060286124A1 (en) * 2004-06-30 2006-12-21 Id Biomedical Corporation Of Quebec Vaccine compositions and methods of treating coronavirus infection
US20060228233A1 (en) * 2005-03-31 2006-10-12 Arimitsu Of North America, Inc. Pump and motor assembly

Also Published As

Publication number Publication date
DE60238471D1 (de) 2011-01-13
ATE489968T1 (de) 2010-12-15
CA2438425A1 (en) 2002-09-19
JP2007031457A (ja) 2007-02-08
WO2002072012A3 (en) 2003-02-27
WO2002072012A2 (en) 2002-09-19
CA2438425C (en) 2012-05-01
JP2004521925A (ja) 2004-07-22
US20090252762A1 (en) 2009-10-08
JP4137640B2 (ja) 2008-08-20
EP1372706B1 (en) 2010-12-01
US20030044425A1 (en) 2003-03-06
EP1372706A4 (en) 2004-08-25
AU2002245636B2 (en) 2004-10-14
US7524509B2 (en) 2009-04-28
EP1372706A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
MXPA03008154A (es) Novedoso adyuvante de vacuna de proteosoma-liposacarido.
EP1333858B8 (en) Vaccines with enhanced immune response and methods for their preparation
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
DK0764029T3 (da) Proteinadjuvanser
MY125387A (en) Vaccine
ZA956412B (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
EP1504112A4 (en) DEVELOPMENT OF A VACCINE FOR THE PREVENTION OF INFECTIONS WITH THE FILOVIRUS IN PRIMATES
HK1121382A1 (en) Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines
CA2059692A1 (en) Pneumoccoccal polysaccharide conjugate vaccine
MX9702336A (es) Composiciones de vacuna.
CA2311492A1 (en) Vaccines with an ltb adjuvant
EP1395283A4 (en) HETEROLOGOUS PROTECTION INDUCED BY IMMUNIZATION WITH INVAPLEX VACCINE
EP1438066A4 (en) IMMUNOGENIC COMPOSITIONS OF ENTIRE CELLS OF REACTIVE BACTERIA
WO1999011660A3 (en) Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
EP0270295A3 (en) Conjugate vaccine
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
HK1025220A1 (en) Novel saponin compositions and uses thereof
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
WO2001040472A3 (en) Streptococcus pneumoniae antigens
EP1401493B8 (en) Subunit vaccines and processes for the production thereof
CA2112225A1 (en) Attenuated revertant serotype 1 marek's disease vaccine
Smirnova et al. Vibrio cholerae strains, serogroups O 1 and O 139, as productive of major protective antigens
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal